<a href= "https://peterattiamd.com/keithflaherty2/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=230821-pod-keithflaherty2&utm_content=230821-pod-keithflaherty2-podfeed"> View the Show Notes Page for This Episode</a> <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=230821-pod-keithflaherty2&utm_content=230821-pod-keithflaherty2-podfeed"> Become a Member to Receive Exclusive Content</a> <a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=230821-pod-keithflaherty2&utm_content=230821-pod-keithflaherty2-podfeed"> Sign Up to Receive Peter’s Weekly Newsletter</a> Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this episode, Keith first delves into the statistics on cancer's prevalence as we age, underscoring the significance of finding effective treatments and early detection methodologies. He touches on the history of cancer therapeutics and illuminates the notable enhancements in cancer therapy within the last decade that are setting the stage for a promising future. He goes into detail on the potential of immunotherapy and therapies that can combat cancer’s evasive tactics while explaining some of the existing challenges around specificity, cost, and scalability. Additionally, Keith highlights the significant leap in early detection methodologies, namely liquid biopsies, which have the potential not only to determine if a cancer is present in an early stage, but also identify the possible tissue of origin. We discuss: <ul type="disc"> <li>Keith’s interest and expertise in cancer [3:15];</li> <li>Cancer deaths by decade of life, and how cancer compares to other top causes of death [7:00];</li> <li>The relationship between hormones and cancer [12:00];</li> <li>The link between obesity and cancer [18:45];</li> <li>Current state of treatments for metastatic cancer and reasons for the lack of progress over the decades [22:30];</li> <li>The interplay between the immune system and cancer cells [32:00];</li> <li>Different ways cancer can suppress the immune response, and how immunotherapy can combat cancer’s evasive tactics [39:30];</li> <li>Elimination of a substantial portion of cancers through immune cell engineering faces challenges of specificity, cost, and scalability [52:15];</li> <li>Why TIL therapy isn’t always effective, and the necessity for multimodal therapy to address various aspects of the cancer microenvironment [1:01:00];</li> <li>Potential developments in cancer therapy over the next five years: T-cell activation, metabolic interventions, targeting tumor microenvironments, and more [1:06:30];</li> <li>The challenge of treating metastatic cancer underscores the importance of early detection to improve survivability [1:19:15];</li> <li>Liquid biopsies for early detection of cancer and determining the possible tissue of origin [1:24:45];</li> <li>Commercially available cancer screening tests [1:33:45];</li> <li>How to address the disparity in cancer care, and the exciting pace of progress for cancer detection and treatment [1:40:15]; and</li> <li>More.</li> </ul> Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

#267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.

The Peter Attia Drive

AI Chapters

AI Insights

Reviews